Immunotherapy plus endostatin and chemo for stage III lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of an immunotherapy drug (tislelizumab), an anti-angiogenic drug (endostatin), and standard chemotherapy for people with stage III lung cancer that cannot be surgically removed. The goal is to see if this triple therapy can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have stage III non-small cell lung cancer that cannot be removed by surgery.
- This is your first treatment for this lung cancer – you cannot have had chemotherapy, radiation, or other drugs for it before.
- Your cancer should not have certain gene changes (like EGFR, ALK, ROS1, RET, HER2, or MET). If you have non-squamous type, these gene tests must be done.
- You must be between 18 and 75 years old, in good enough health to get chemotherapy (ECOG score 0-1), and have at least one tumor that can be measured.
- Your kidney, liver, and blood cell counts must be within certain limits, and you must not have had serious bleeding or blood clots recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a combination of an immunotherapy drug (serplulimab) and chemotherapy before any surgery can help shrink tumors in people with stage III lung cancer that can't be removed. The goal is to make the cancer easier to treat and improve outcomes.
This trial combines an immunotherapy drug (tislelizumab) with chemotherapy before surgery to try to shrink the tumor and possibly make surgery possible later. The goal is to improve outcomes for people with stage III non-small cell lung cancer that is not removable at diagnosis.
This study tests a new approach: giving an immunotherapy drug (tislelizumab) plus chemotherapy before surgery or radiation for advanced lung cancer that has spread to chest lymph nodes. The goal is to shrink the cancer first, then remove or treat it, to improve chances of long-term control.
This trial tests a new schedule of chemo-radiation (fewer, stronger sessions) followed by an immunotherapy drug called tislelizumab. The goal is to see if this approach works better than the standard longer schedule for people with stage III lung cancer that can't be surgically removed.
This trial tests a combination of two immunotherapy drugs plus chemotherapy to shrink lung tumors so they can be removed with surgery. The goal is to give patients with stage III unresectable non-small cell lung cancer a chance at surgery and a better outcome.
This trial tests whether giving a combination of two immunotherapy drugs with chemotherapy before surgery can help shrink stage III lung cancer and improve outcomes. It is for people whose cancer has spread to lymph nodes in the chest but can still be removed with surgery.
Hear when a new Unresectable Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.